A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Acalabrutinib (Primary) ; Bendamustine; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 28 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 28 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top